中國抗體-B(03681.HK)擬折讓約11.29%發行合共1.13億股 籌資約1.24億港元
格隆匯5月13日丨中國抗體-B(03681.HK)公告,於2025年5月13日,公司與二十六名認購人(均爲獨立第三方)訂立二十六(26)份認購協議,據此,認購人有條件同意認購而公司有條件同意發行合共1.13億股認購股份,每股認購價爲港幣1.10元。認購股份相當於(i)公司於本公告日期的已發行股本約10.33%;及(ii)公司經發行認購股份擴大的已發行股本約9.37%。每股認購股份認購價爲港幣1.10元,較5月13日在聯交所所報每股收市價港幣1.240元折讓約11.29%。
認購事項所得款項淨額合共將約爲港幣1.24億元。公司擬將所得款項淨額用於以下用途:(i)45%用於SM17的研發及臨牀項目以及潛在國際合作,特別是在中國進行特應性皮炎的皮下橋接研究及二期臨牀研究,以支付試驗費用、相關生產成本及相關僱傭成本;(ii)20%用於目前不在公司的產品線內的新候選藥物的臨牀前研究、臨牀試驗、相關生產、註冊申報的準備工作及相關僱傭成本,以使公司的產品組合多元化,以及用於新候選藥物的IND申報準備工作,特別是用於臨牀前研究、生產成本及相關僱傭成本;及(iii)35%用作一般營運資金。
董事認爲,認購事項爲公司籌集資金以滿足公司資金需求及加強公司股權基礎的良機。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.